In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus Cadila Reels After Double FDA Warning

This article was originally published in PharmAsia News

Executive Summary

Shares of Cadila Healthcare were pounded on Indian bourses on New Year's Eve after the US FDA issued warning letters against two of the firm's Indian sites, though the company's top brass stressed that de-risking efforts, by way of site transfers for critical products, were already underway.

You may also be interested in...



Zydus Cadila Chief Passes On Baton To Scion

Cadila Healthcare’s scion Dr Sharvil Patel takes charge as managing director as the frontline Indian company transitions to its next phase of growth and aspires for a more innovation-driven avatar.

Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma

Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Tripartite Avigan Alliance Aims For Global Access

Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel